Promising data for Vicore's oral coronavirus treatment

8 December 2020

2020_pills_tablets_bottles_biotech_manufacturing_production_big

Swedish lung specialist Vicore Pharma (VICO: STO) has unveiled positive data from the ATTRACT COVID-19 trial of C21 (VP01), an oral treatment for the novel coronavirus.

Shares in the Gothenburg-based firm rose by a quarter in Stockholm on Tuesday morning following the news.

Vicore is testing C21, a first-in-class angiotensin II type 2 receptor (AT2R) agonist, in people with signs of an acute respiratory infection but who do not require mechanical ventilation.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK